News

Breakthrough in Hypoxic Modification for Head and Neck Cancer Patients

Vienna, Austria – May 5, 2025 Breakthrough in Hypoxic Modification for Head and Neck Cancer Patients receiving Chemoradiation Treatment Presented at ESTRO 2025. Clinical Study Demonstrates Improved Locoregional Control with Nimorazole in Advanced Head and Neck Cancer....

Lunatus and AFYX Therapeutics A/S Announce Distribution and Sales Collaboration

Hørsholm, Denmark – April 23, 2025 Lunatus and AFYX Therapeutics A/S are pleased to announce a new distribution and sales collaboration for AFYX's induction of labor product, Gefena (Misoprostol 25μg tablet). Under this agreement, Lunatus will distribute,...

Interim Financial Report Q4 2024

In Q4 2024, AFYX Group reported total revenue of DKK 12.9 million, up from DKK 8.9 million in Q4 2023. The increase was driven primarily by higher sales of Diaphine, along with growth in Nimorazole sales, largely attributed to our customers in Norway—a trend we expect...

AFYX Therapeutics A/S Secures DKK 25 million in Funding

Copenhagen, Denmark – December 19, 2024 AFYX Therapeutics A/S, a pioneering Danish biopharmaceutical company specializing in reversed innovation and the repurposing of established pharmaceutical substances, has successfully raised DKK 25 million in its latest funding...

Genmab founder dreams again of IPO of biotech company

After a sudden exit from Y-Mabs Therapeutics, Claus Møller has been quite silent for two years. Now he is building a new biotech company. Claus Møller, who helped found Genmab, has now started a new biotech adventure with Afyx Therapeutics. Claus Møller-San Pedro, who...

AFYX completes financing round of DKK 13.7M

Hørsholm, Denmark, April 15, 2024 After our recent Annual General Meeting the BOD has now in cooperation with the CEO completed an internal financing round to secure the financial basis for the transformation of our company to become an international growth and...

AFYX report from our Annual General Meeting

Hørsholm, Denmark, April 03, 2024 As of August 2023, Dr. Claus Møller-San Pedro took over as the new CEO of Inphena ApS, now a part of AFYX Therapeutics A/S. During an Extraordinary General Meeting in December 2023 our Board of Directors (BOD) was expanded to 3...

Inphena has acquired all shares in AFYX Therapeutics

Hørsholm, Denmark, January 09, 2024 Today, we are happy to announce that Inphena A/S has acquired all shares in AFYX Therapeutics A/S. The transaction came in place after the majority shareholders Sofinnova, Novo Holdings and the Lundbeck Foundation decided that the...